U.S. markets open in 1 hour 58 minutes
  • S&P Futures

    4,575.50
    -0.25 (-0.01%)
     
  • Dow Futures

    34,631.00
    +9.00 (+0.03%)
     
  • Nasdaq Futures

    15,986.75
    -1.75 (-0.01%)
     
  • Russell 2000 Futures

    2,207.10
    +1.90 (+0.09%)
     
  • Crude Oil

    68.30
    +1.80 (+2.71%)
     
  • Gold

    1,773.30
    +10.60 (+0.60%)
     
  • Silver

    22.32
    +0.04 (+0.18%)
     
  • EUR/USD

    1.1313
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    1.4480
    0.0000 (0.00%)
     
  • Vix

    27.62
    -3.50 (-11.25%)
     
  • GBP/USD

    1.3262
    -0.0041 (-0.31%)
     
  • USD/JPY

    113.3600
    +0.1510 (+0.13%)
     
  • BTC-USD

    56,993.89
    +506.51 (+0.90%)
     
  • CMC Crypto 200

    1,455.52
    +16.64 (+1.16%)
     
  • FTSE 100

    7,156.12
    +26.91 (+0.38%)
     
  • Nikkei 225

    28,029.57
    +276.20 (+1.00%)
     
  • Oops!
    Something went wrong.
    Please try again later.

Eli Lilly antibody trial paused due to potential safety concern

·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Oct 13 (Reuters) - U.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.

"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study."

Lilly shares were down about 3% at $150. (Reporting by Michael Erman in New York; Editing by Bill Berkrot)